ストックスクリーナーアプリを入手
137.28
10.90%
-16.80
プレマーケット:
135.50
-1.78
-1.30%
前日終値:
$154.08
開ける：
$159.43
24時間の取引高:
2.02M
Relative Volume:
2.32
時価総額：
$6.13B
収益：
$156.12M
当期純損益:
$-395.33M
株価収益率:
-13.23
EPS:
-10.3758
ネットキャッシュフロー:
$-292.33M
1週間 パフォーマンス:
+0.52%
1か月 パフォーマンス:
+70.87%
6か月 パフォーマンス:
+165.33%
1年 パフォーマンス:
+122.50%
1日の値動き範囲:
$135.80
$166.47
1週間の範囲:
$132.04
$166.47
52週間の値動き範囲:
$41.50
$166.47
Grail Inc Stock (GRAL) Company Profile
Compare GRAL vs TMO, DHR, NTRA, A, WAT
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
137.28 | 5.67B | 156.12M | -395.33M | -292.33M | -10.38 |
TMO
Thermo Fisher Scientific Inc
|
656.58 | 241.26B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
215.61 | 150.48B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
400.65 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
169.33 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
WAT
Waters Corp
|
436.43 | 42.59B | 3.77B | 449.25M | 240.68M | 7.8556 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-10 | 開始されました | Mizuho | Neutral |
| 2026-03-18 | アップグレード | TD Cowen | Hold → Buy |
| 2026-02-19 | 開始されました | TD Cowen | Hold |
| 2026-02-17 | 開始されました | Robert W. Baird | Outperform |
| 2025-12-02 | 再開されました | Morgan Stanley | Equal-Weight |
| 2025-11-12 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-04-21 | 開始されました | Canaccord Genuity | Buy |
| 2024-11-27 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-10-17 | 開始されました | Guggenheim | Neutral |
すべてを表示
Grail Inc (GRAL) 最新ニュース
A Cancer Test Has Investors Betting Big. But Will Insurers Pay? - WSJ
The Galleri MCD vote: What FDA asked its advisors to ignore - The Cancer Letter
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October - The Motley Fool
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October - The Motley Fool
Grail Stock Has Soared 180% in 6 Months. Here's Why the Stock Has More Room to Run. - Yahoo Finance
This Stock, Up Almost 70%, May Have Found Cancer's Holy 'Grail' - Investor's Business Daily
Is GRAIL (GRAL) Expensive Following PATHFINDER 2 Results And The FDA Panel Vote? - Simply Wall Street
GRAL Stock Rockets Higher As Traders Hunt Momentum - StocksToTrade
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone - Stocktwits
GRAIL: AdCom's Vote Of Confidence Is Significant (NASDAQ:GRAL) - Seeking Alpha
Grail's stock jumps 55% after positive FDA advi... - Pluang
Grail stock price target raised to $150 by Canaccord on FDA outlook - Investing.com
FDA Advisory Panel Votes to Approve GRAIL Galleri MCED Screening Test - Oncology Nursing News
Grail CEO Joshua Ofman sells $6.0m in company stock on Sept. 21 By Investing.com - Investing.com South Africa
Form 4 Grail Inc For: 26 September By Investing.com - Investing.com Australia
Grail CFO Aaron Freidin sells $382,679 in company stock By Investing.com - Investing.com South Africa
Grail CEO Joshua Ofman sells $6.0m in company stock on Sept. 21 - Investing.com
FDA Advisory Panel Backs Approval of GRAIL’s Galleri Multi-Cancer Early Detection Test - clpmag.com
Just a Flesh Wound: The Combative Quest for Cancer’s Holy Grail - Inside Precision Medicine
FDA advisory panel endorsed Grail's multi-cancer blood test in a split vote - qz.com
FDA panel endorses Grail Galleri multi-cancer blood test - Yahoo
Mizuho raises Grail stock price target to $100 on FDA panel vote - Investing.com Canada
Mizuho raises Grail stock price target to $100 on FDA panel vote By Investing.com - Investing.com South Africa
Here's Why Grail Stock Surged 55% This Week - The Motley Fool
Canaccord Genuity Remains a Buy on GRAIL Inc (GRAL) - theglobeandmail.com
GRAIL's Galleri Cancer Test Clears FDA Panel On Safety, Narrowly Backed On Effectiveness: GRAL Stock In Focus - Stocktwits
Grail multicancer detection test wins FDA advisers’ backing - BioPharma Dive
This Controversial Cancer Test Just Passed a Key FDA Vote. Here's Why It's Dividing Experts - inc.com
GRAIL (GRAL) Wins FDA Panel Backing, Is It Now Overvalued? - Yahoo Finance
Grail Surges After FDA Advisors Back Its Cancer-Finding Blood Test - Investor's Business Daily
FDA-endorsed blood test can spot early signs of more than 50 types of cancer, drugmaker says - FOX 10 Phoenix
GRAL Stock Surges As Traders Target High-Momentum Breakout - timothysykes.com
GRAL Stock Rockets As Traders Chase Breakout Momentum - StocksToTrade
FDA Panel Endorses GRAIL Galleri Cancer Screening Tool - Benzinga
Grail Shares Gain as FDA Panel Votes to Support Cancer Detection Test - marketscreener.com
One blood test could screen you for 50 cancers. Here’s why it’s controversial. - The Washington Post
Grail stock hits all-time high at 119.09 USD - Investing.com
FDA Advisors Said It Should Approve the Grail Multicancer Blood Test. The Stock Rises Sharply. - Barron's
Grail stock hits all-time high at 119.09 USD By Investing.com - Investing.com Canada
Canaccord reiterates Buy on Grail stock after FDA panel vote - Investing.com
GRAIL Surges As FDA Panel Backs Cancer Blood Test - TipRanks
What is next for Grail stock after surging on positive FDA comments? - Investing.com
FDA panel endorses first-of-a-kind cancer blood test from Grail - Daily Herald
Grail survives adcomm vote as it awaits FDA decision for cancer blood test - Fierce Biotech
FDA advisory panel backs GRAIL's Galleri multi-cancer early detection test - allsci.com
Canaccord reiterates Buy on Grail stock after FDA panel vote By Investing.com - Investing.com Nigeria
Grail MCED Test is Safe, Effective, Experts Tell FDA, While Questioning ‘Early Detection’ Claim - GenomeWeb
FDA panel endorses GRAIL’s multi-cancer early detection test - yahoo.com
Premarket movers: Stitch Fix tumbles, Grail surges - Investing.com
Why is Grail stock surging today? - Investing.com
FDA panel backs Galleri blood test that screens for more than 50 cancers - Straight Arrow
Grail Inc (GRAL) 財務データ
収益
当期純利益
現金流量
EPS
0.99%
0.56%
大文字化:
|
ボリューム (24 時間):